How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
DHA Supplements Market
- By Source: Fish Oil, Algal Oil, Krill Oil, Egg Oil, Other Marine Sources
- By Form: Softgel Capsules, Liquid Oil, Powder, Tablets, Chewables
- By Application: Infant Nutrition, Dietary Supplements, Functional Food & Beverages, Pharmaceuticals
- By End User: Infants & Toddlers, Pregnant & Lactating Women, Adults, Elderly
- By Distribution Channel: Pharmacies & Drug Stores, Supermarkets & Hypermarkets, Online Retail, Specialty Stores
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Fish Oil leads By Source at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the DHA Supplements Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Source 5
Form 5
Application 4
End User 4
Distribution Channel 4
Companies profiled
DSM Nutritional Products
Croda International Plc
Omega Protein Corporation
Martek Biosciences Corporation (a subsidiary of DSM)
Cargill
Incorporated
BASF SE
Alaska Omega
Epax Norway AS
Qualitas Health
GC Rieber Oils
Nissui Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →DSM Nutritional Products
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Croda International Plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Omega Protein Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Martek Biosciences Corporation (a subsidiary of DSM)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cargill
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Alaska Omega
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Epax Norway AS
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Qualitas Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →GC Rieber Oils
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Nissui Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Lonza Group AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Enzymotec Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Omega Alpha Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Nutraceutical Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,564M by 2033 · 10.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Fish Oil40.3
- Algal Oil19.4
- Krill Oil9.5
- Egg Oil12.6
- Other Marine Sources18.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$851.8M → $1,980M · 11.1%
Europe$593.7M → $1,152M · 8.6%
Asia Pacific$542.1M → $1,064M · 8.8%
Latin America$335.6M → $750.3M · 10.6%
Middle East and Africa$258.1M → $529.1M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.022026
10.042027
10.052028
10.062029
10.072030
10.092031
10.102032
10.102033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- DSM Nutritional Products9.7
- Croda International Plc17.9
- Omega Protein Corporation13.5
- Martek Biosciences Corporation (a subsidiary of DSM)6.2
- Cargill10.9
- Incorporated13.9
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Source28.3%
Form8.9%
Application19.3%
End User25.0%
Distribution Channel18.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.2
- Europe21.0
- Asia Pacific19.4
- Latin America13.7
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| DSM Nutritional Products | 95 | 82 | 82 | 95 | 75 | 93 | 87 |
| Croda International Plc | 92 | 72 | 69 | 73 | 85 | 71 | 77 |
| Omega Protein Corporation | 85 | 70 | 84 | 87 | 86 | 82 | 82 |
| Martek Biosciences Corporation (a subsidiary of DSM) | 79 | 71 | 64 | 74 | 81 | 70 | 73 |
| Cargill | 56 | 56 | 61 | 63 | 69 | 76 | 64 |
| Incorporated | 55 | 63 | 63 | 70 | 55 | 69 | 63 |
| BASF SE | 48 | 53 | 49 | 49 | 55 | 42 | 49 |
| Alaska Omega | 41 | 52 | 44 | 60 | 48 | 37 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- DSM Nutritional Products
- Croda International Plc
- Omega Protein Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| DSM Nutritional Products | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Croda International Plc | ✓ | ◐ | − | ◐ | ✓ | ✓ |
| Omega Protein Corporation | ✓ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Martek Biosciences Corporation (a subsidiary of DSM) | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Cargill | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Incorporated | − | ◐ | ◐ | ◐ | ◐ | − |
| BASF SE | − | − | − | ◐ | − | − |
| Alaska Omega | ◐ | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1DSM Nutritional Products87
2Omega Protein Corporation82
3Croda International Plc77
4Martek Biosciences Corporation (a subsidiary of DSM)73
5Cargill64
6Incorporated63
7BASF SE49
8Alaska Omega47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
DSM Nutritional ProductsOmega Protein Corporation
Challenger2
Strong scale, closing on the leaders.
Croda International PlcMartek Biosciences Corporation (a subsidiary of DSM)
Contender2
Focused players with pockets of strength.
CargillIncorporated
Niche2
Specialists in a single segment or region.
BASF SEAlaska Omega
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Source in North America, then scale across DHA Supplements Market — a $347M beachhead inside a $6.43B market.
Beachhead (SOM)$347Mobtainable near-term
Serviceable (SAM)$2.23Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Fish Oil
Best fit — highest urgency & budget in Source.
Economic buyer78 fit
Algal Oil
Strong fit — clear ROI and a fast path to value.
End user68 fit
Krill Oil
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Source in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Form & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel26%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Source leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win DHA Supplements Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified22%
Evaluation13%
Closed-won6%
$9.9KCAC
$41KLTV
4.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
DHA Supplements Market is a durable-growth opportunity — $7.81B by 2033, compounding at 6.9%.
TAM · 2025$4.57Btoday
TAM · 2033$7.81Bforecast
CAGR6.9%2027–2033
Cumulative$54.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.81BTotal addressable market
SAM$2.66BServiceable available market
SOM$466MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.9% CAGR
Demand compounds through 2033, outpacing GDP across Source.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Source moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.81BLarge & growingTAM by 2033 at 6.9% CAGR
$2.66BServiceable nowreachable with today’s model
$466MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.09BBear4.5% CAGR
$7.81BBase6.9% CAGR
$9.99BBull9.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Form optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
DHA Supplements Market — a $7.57B market by 2033. Plan: grow share from 6.3% to 11.2%.
Market size · 2033$7.57Btotal addressable
Market CAGR6.1%2027–2033
Target share11.2%from 6.3% today
Revenue ambition$848Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.3% | 11.2% | Behind |
| Revenue | $473M | $848M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 28.4% | 40.1% | Ahead |
| Customer retention | 88.5% | 94.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Source
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Form capability
A defensible second engine — invest in Form to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Source share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Form
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $96M capacity & capability investment
- Greenlight bolt-on M&A in Form
- Authorise North America expansion plan
- Fund R&D program for Source leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the DHA Supplements Market conversation — a $1.06B market you can size, segment and defend in minutes.
Market size · 2033$1.06Btotal opportunity
Growth8.4%CAGR to 2033
Addressable buyers1,057+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Source
Goal Grow share in Source
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 3 mopayback period
$83K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
DSM Nutritional ProductsCroda International PlcOmega Protein CorporationMartek Biosciences Corporation (a subsidiary of DSM)CargillIncorporatedBASF SEAlaska Omega+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your DHA Supplements Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
DHA Supplements Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Decongestant Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCorneal Graft Rejection Drug Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportFat Metaboliser Tablets Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCorifollitropin Alfa Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportFast-disintegrating Tablets Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportFast-dissolving Tablets Market
Market size, share, segmentation and regional forecast.
$489M market · 2025 base year
View reportFarm Animal Internal Medicine Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportConjunctivitis Drugs Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportClarityne Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportClarithromycin Tablets Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportCharcot-Marie-Tooth Disease Type I A Drug Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportDual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.